The effect of administration of DBO-83 on memory processes was evaluated in the mouse passive avoidance test. DBO-83 (1-5 mgkg-1 ip) prevented amnesia induced by scopolamine (1.5 mgkg-1 ip), mecamylamine (20 mgkg-1 ip) and dihydro-β-erythroidine (10 μg per mouse i.c.v.). In the same experimental conditions, DBO-83 (10 mgkg-1 ip) also prevented baclofen (2 mgkg-1 ip), clonidine (0.125 mgkg-1 ip) and diphenhydramine (20 mgkg-1 ip) amnesia in mice. The antiamnesic effect of DBO-83 was comparable to that exerted by nicotine (2 mgkg-1 ip), physostigmine (0.2 mgkg-1 ip), and the nootropic drug, piracetam (30 mgkg-1 ip). In the antiamnesic dose-range, DBO-83 did not impair mouse motor coordination and spontaneous motility, as revealed, respectively, by the Animex apparatus and rotarod test. These results demonstrated the ability of DBO-83 to modulate memory functions and suggest that DBO-83 could be useful in the treatment of cognitive deficits.
Antiamnesic activity of the nicotinic agonist DBO-83 in mice / C. Ghelardini, N. Galeotti, F. Giuliani, D. Barlocco, A. Bartolini. - In: DRUG DEVELOPMENT RESEARCH. - ISSN 0272-4391. - 45:2(1998), pp. 45-51. [10.1002/(SICI)1098-2299(199810)45:2<45::AID-DDR1>3.0.CO;2-Q]
Antiamnesic activity of the nicotinic agonist DBO-83 in mice
D. BarloccoPenultimo
;
1998
Abstract
The effect of administration of DBO-83 on memory processes was evaluated in the mouse passive avoidance test. DBO-83 (1-5 mgkg-1 ip) prevented amnesia induced by scopolamine (1.5 mgkg-1 ip), mecamylamine (20 mgkg-1 ip) and dihydro-β-erythroidine (10 μg per mouse i.c.v.). In the same experimental conditions, DBO-83 (10 mgkg-1 ip) also prevented baclofen (2 mgkg-1 ip), clonidine (0.125 mgkg-1 ip) and diphenhydramine (20 mgkg-1 ip) amnesia in mice. The antiamnesic effect of DBO-83 was comparable to that exerted by nicotine (2 mgkg-1 ip), physostigmine (0.2 mgkg-1 ip), and the nootropic drug, piracetam (30 mgkg-1 ip). In the antiamnesic dose-range, DBO-83 did not impair mouse motor coordination and spontaneous motility, as revealed, respectively, by the Animex apparatus and rotarod test. These results demonstrated the ability of DBO-83 to modulate memory functions and suggest that DBO-83 could be useful in the treatment of cognitive deficits.Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.